Literature DB >> 18722309

The impact of diabetes on perioperative patient outcomes after total hip and total knee arthroplasty in the United States.

Michael P Bolognesi1, Milford H Marchant, Nicholas A Viens, Chad Cook, Ricardo Pietrobon, Thomas Parker Vail.   

Abstract

The purpose of this study was to determine whether patients with diabetes mellitus (DM) have a higher likelihood of immediate, inpatient complications following primary and revision total hip (THA) and total knee arthroplasty (TKA) than patients without DM. From 1988 to 2003, the Nationwide Inpatient Sample identified 751340 primary or revision THA or TKA patients. 64262 (8.55%) had DM. Comparisons of specific outcome measures between diabetic and nondiabetic cohorts were performed using bivariate and multivariate analyses with logistic regression modeling. Diabetic patients had fewer routine discharges and higher inflation-adjusted hospital charges for all procedures. Although complications were not uniformly increased, diabetic patients had significantly increased odds of pneumonia, stroke, and transfusion (P < .001) after primary arthroplasty. This analysis of a large patient database indicates clinically relevant information for patients and surgeons, suggesting that patients undergoing THA and TKA demonstrate more complications and utilize more resources if they have the comorbidity of DM level II evidence.

Entities:  

Mesh:

Year:  2008        PMID: 18722309     DOI: 10.1016/j.arth.2008.05.012

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  49 in total

1.  The potential utility of patient-reported range of motion after total knee arthroplasty.

Authors:  Jack Weick; Harpreet S Bawa
Journal:  Ann Transl Med       Date:  2015-08

Review 2.  The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms.

Authors:  K B King; A K Rosenthal
Journal:  Osteoarthritis Cartilage       Date:  2015-03-30       Impact factor: 6.576

3.  [Complications after hip operations].

Authors:  B-D Katthagen; A-R Zahedi
Journal:  Orthopade       Date:  2009-09-03       Impact factor: 1.087

4.  Identifying high-cost episodes in lower extremity joint replacement.

Authors:  Lindsey M Philpot; Kristi M Swanson; Jonathan Inselman; William J Schoellkopf; James M Naessens; Bijan J Borah; Stephanie Peterson; Barbara Gladders; Nilay D Shah; Jon O Ebbert
Journal:  Health Serv Res       Date:  2018-11-05       Impact factor: 3.402

Review 5.  Improving Quality and Decreasing Cost by Reducing Re-admissions in Patients Undergoing Total Joint Arthroplasty.

Authors:  Daniel S Sveom; Mary K Otteman; Kevin L Garvin
Journal:  Curr Rev Musculoskelet Med       Date:  2017-09

Review 6.  [Characteristics of elective hip replacement in the elderly].

Authors:  T Claßen; C Scheid; S Landgraeber; M Jäger
Journal:  Orthopade       Date:  2017-01       Impact factor: 1.087

7.  Do glycemic markers predict occurrence of complications after total knee arthroplasty in patients with diabetes?

Authors:  Ji Sup Hwang; Seok Jin Kim; Ankur B Bamne; Young Gon Na; Tae Kyun Kim
Journal:  Clin Orthop Relat Res       Date:  2014-11-18       Impact factor: 4.176

8.  Analysis of a large data set to identify predictors of blood transfusion in primary total hip and knee arthroplasty.

Authors:  ZeYu Huang; Cheng Huang; JinWei Xie; Jun Ma; GuoRui Cao; Qiang Huang; Bin Shen; Virginia Byers Kraus; FuXing Pei
Journal:  Transfusion       Date:  2018-08-25       Impact factor: 3.157

9.  Surgical Risks and Costs of Care are Greater in Patients Who Are Super Obese and Undergoing THA.

Authors:  Menachem M Meller; Nader Toossi; Mark H Gonzalez; Min-Sun Son; Edmund C Lau; Norman Johanson
Journal:  Clin Orthop Relat Res       Date:  2016-08-25       Impact factor: 4.176

10.  Predictors of range of motion in patients undergoing manipulation after TKA.

Authors:  Harpreet S Bawa; Glenn D Wera; Matthew J Kraay; Randall E Marcus; Victor M Goldberg
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.